Department of Neurology, Neuroimmunology and Multiple Sclerosis Unit, Health Research Institute (IdiPAZ), University Hospital La Paz/Autónoma University of Madrid, Madrid, Spain.
Expert Rev Neurother. 2012 Apr;12(4 Suppl):3-8. doi: 10.1586/ern.12.11.
Multiple sclerosis (MS) is associated with a wide range of disease symptoms and amongst these, spasticity is one of the most disabling and has the greatest impact on patient well-being and quality of life. Until now, available drug therapies for spasticity appear to have limited benefit and are often associated with poor tolerability. In a recent Spanish survey it was noted that multidrug therapy and a low control rate were common features for a large proportion of patients with MS-related spasticity, suggesting that currently available monotherapies lack significant activity. Sativex is a 1:1 mixture of δ-9-tetrahydrocannabinol and cannabidiol derived from Cannabis sativa chemovars, which is available as an oromucosal spray. Clinical experience with Sativex in patients with MS-related spasticity is steadily accumulating. Results from randomized, controlled trials have reported a reduction in the severity of symptoms associated with spasticity, leading to a better ability to perform daily activities and an improved perception of patients and their carers regarding functional status. These are highly encouraging findings that provide some much needed optimism for the treatment of this disabling and often painful symptom of MS.
多发性硬化症（MS）与广泛的疾病症状相关，其中痉挛是最具致残性的症状之一，对患者的幸福感和生活质量有重大影响。到目前为止，痉挛的现有药物疗法似乎益处有限，而且通常与较差的耐受性相关。在最近的一项西班牙调查中注意到，对于很大一部分多发性硬化症相关痉挛患者来说，多药物治疗和低控制率是常见特征，这表明目前可用的单药治疗缺乏显著的疗效。Sativex 是一种从大麻属植物化学变种中提取的 δ-9-四氢大麻酚和大麻二酚的 1:1 混合物，以口腔黏膜喷雾的形式提供。在多发性硬化症相关痉挛患者中使用 Sativex 的临床经验正在稳步积累。随机对照试验的结果报告了与痉挛相关的症状严重程度的降低，从而提高了日常活动的能力，并改善了患者及其护理人员对功能状态的感知。这些令人鼓舞的发现为治疗多发性硬化症这种致残性和常伴有疼痛的症状提供了一些急需的乐观前景。
